With median levels of 234 vs. 156 ng/mL, plasmin-α2-antiplasmin complex (PAP) levels were higher in the SVT MPN+ cohort than in healthy controls (p = 0.0163) but did not differ statistically significantly between the SVT MPN+ and SVT MPN− cohorts and between the SVT MPN− cohort and the control group (Table 2, Figure 2F). The gene discussed is PLG; the disease is myeloproliferative disorder.